Medically reviewed by Dr. Tom Biernacki, DPM — Board-Certified Podiatric Surgeon — Balance Foot & Ankle, Howell & Bloomfield Hills, MI. Last updated April 2026.

Tophi — subcutaneous deposits of monosodium urate (MSU) crystals — are the defining feature of chronic tophaceous gout, representing years of sustained hyperuricemia that has exceeded the body’s capacity for urate solubility. In the foot, tophi most commonly develop at the first metatarsophalangeal joint, olecranon bursa equivalent (over the distal Achilles and posterior heel), interdigital spaces, and plantar surface. Tophi cause progressive joint destruction, tendon infiltration, skin erosion, and secondary infection — representing uncontrolled gout disease that requires both medical and podiatric management. The podiatrist’s role in tophaceous gout is both therapeutic (managing the mechanical consequences of tophi on foot function and preventing complications) and preventive (monitoring and documenting tophus regression in response to urate-lowering therapy).

Tophus Pathology in the Foot

Tophi grow slowly over years to decades when serum uric acid remains elevated above 6.8 mg/dL (the solubility threshold). Monosodium urate crystals within tophi are not inert — they continue to trigger chronic low-grade inflammatory responses that erode articular cartilage, periarticular bone, and tendon tissue. First MTP tophi produce the characteristic radiographic “punched-out” erosions with overhanging edges and preservation of joint space until late disease. Achilles tendon tophi — depositing within the tendon substance — dramatically increase Achilles rupture risk, particularly when the tophus is large (greater than 2 cm), centrally located, or associated with local steroid injection (which further weakens the surrounding tendon tissue). Plantar tophi can ulcerate through the skin when internal pressure from crystal growth exceeds tissue tensile strength, creating draining sinuses that continuously discharge chalky white tophaceous material.

Conservative Tophus Management

The primary treatment for tophaceous gout is aggressive urate-lowering therapy (ULT) targeting serum uric acid below 5.0 mg/dL (the tophus dissolution target — lower than the standard arthritis prevention target of 6.0 mg/dL). Progressive tophus reduction and eventual resolution is documented on serial clinical examination and high-resolution ultrasound or dual-energy CT. Allopurinol (up to 800 mg daily as tolerated), febuxostat, or lesinurad combination therapy is titrated monthly until the target SUA is achieved. Tophus regression begins within 3–6 months of sustained SUA below 5 mg/dL and is complete in 1–3 years for most accessible tophi. Prophylactic colchicine 0.6 mg daily is maintained during ULT initiation and dose escalation to prevent mobilization flares. Podiatric accommodative care includes extra-depth footwear for digital tophi, custom molded insoles with cutouts accommodating bony prominences, and regular wound care for tophi approaching the skin surface.

Surgical Tophus Debulking

Surgical tophus removal is indicated when: tophi are causing skin ulceration with persistent drainage and infection risk, tophus size is limiting ambulation or footwear fitting despite maximal ULT, nerve or vascular compression from tophus is causing functional deficits, or large first MTP tophi with significant bone erosion require surgical débridement and joint reconstruction. Surgical technique involves excision of accessible tophaceous material under tourniquet control — complete removal is rarely achievable as MSU crystals infiltrate tissues at the microscopic level, but surgical debulking reduces tophus burden and allows wound closure. ULT must be continued aggressively postoperatively as surgical debulking without concurrent SUA normalization results in rapid re-accumulation.

Tophaceous Gout Management at Balance Foot & Ankle

Dr. Biernacki at Balance Foot & Ankle manages tophaceous gout foot complications — including tophus accommodation, wound management for draining sinuses, footwear prescription, and coordination with rheumatology for urate-lowering therapy optimization. Tophus size monitoring using clinical examination and ultrasound tracks ULT response. Call (810) 206-1402 for evaluation of gout-related foot problems.

Gout Tophi Affecting Your Feet? Get Expert Management.

Serving Southeast Michigan from Bloomfield Hills and Howell.

📞 (810) 206-1402 |

📧 Get Dr. Tom’s Free Lab Test Guide

Discover the 5 lab tests every person over 35 should ask their doctor about — explained in plain English by a board-certified physician.

Download Your Free Guide →

Book Online →

📍 Located in Michigan?

Our board-certified podiatrists treat this condition at two convenient locations. Same-day appointments often available.

Book Now →
(810) 206-1402

Gout Tophi Treatment in Michigan

Tophi — uric acid crystal deposits in the feet — indicate advanced gout requiring aggressive urate-lowering therapy. Our podiatrists manage foot-related tophi complications and coordinate with rheumatology.

Schedule Your Gout Evaluation → | Book Your Appointment | Call (810) 206-1402

Clinical References

1. Dalbeth N, Pool B, Gamble GD, et al. Cellular characterization of the gouty tophus: a quantitative analysis. Arthritis Rheum. 2010;62(5):1549-1556.
2. Perez-Ruiz F, Dalbeth N, Bardin T, et al. A review of uric acid, crystal deposition disease, and gout. Adv Ther. 2015;32(1):31-41.
3. Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450-2461.

Your Board-Certified Podiatrists

Dr. Tom Biernacki, DPM

Board-Certified · FACFAS

Dr. Carl Jay, DPM

Board-Certified Podiatrist

Dr. Daria Gutkin, DPM

Podiatrist

Dr. Tom Biernacki, DPM

Affiliate Disclosure: This page contains affiliate links to products we recommend. If you purchase through these links, Balance Foot & Ankle may earn a small commission at no additional cost to you. We only recommend products we use with our patients.

Dr. Tom Biernacki, DPM is a double board-certified podiatrist and foot & ankle surgeon at Balance Foot & Ankle Specialists in Southeast Michigan. With over a decade of clinical experience, he specializes in heel pain, bunions, diabetic foot care, sports injuries, and minimally invasive surgery. Dr. Biernacki is a member of the APMA and ACFAS, and his patient education content on MichiganFootDoctors.com and YouTube has reached over one million views.